AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 1480736 — intervention group
Group type: EXPERIMENTAL
Intervention: HAL DIRS‐C (Drug Impairment Rating Scale for Cocaine) administered weekly
Number of subjects: 147
Study 6607603 — intervention group
Group type: EXPERIMENTAL
Intervention: iopamidol
Number of subjects: 60
Study 6607603 — intervention group
Group type: EXPERIMENTAL
Intervention: iothalamate
Number of subjects: 60
Study 6607603 — intervention group
Group type: EXPERIMENTAL
Intervention: diatrizoate
Number of subjects: 60
Study 3752434 — intervention group
Group type: EXPERIMENTAL
Intervention: Triazolam 0.25 mg
Number of subjects: 58
Study 3752434 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam 2 mg
Number of subjects: 58
Study 3752434 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study 28967554 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib
Number of subjects: 615
Study 28967554 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 615
Study 27766596 — intervention group
Group type: EXPERIMENTAL
Intervention: Verum acupuncture (deep needling of specific points)
Number of subjects: 53
Study 27766596 — intervention group
Group type: COMPARATOR
Intervention: Control acupuncture (superficial needling of non-acupuncture points)
Number of subjects: 53
Study 27766596 — intervention group
Group type: EXPERIMENTAL
Intervention: Both acupuncture treatments
Number of subjects: 53
Study 24217938 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral metformin (1,500 mg to 2,000 mg daily)
Number of subjects: 90
Study 24217938 — intervention group
Group type: COMPARATOR
Intervention: Increased insulin dose (control group)
Number of subjects: 90
Study 24217938 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral metformin
Number of subjects: 90
Study 23777757 — intervention group
Group type: EXPERIMENTAL
Intervention: MEG/FA data integration using jICA software
Number of subjects: 0
Study 23777757 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower FA values in bilateral posterior parietal regions
Number of subjects: 0
Study 23777757 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased FA in a right medial frontal region
Number of subjects: 0
Study 23777757 — intervention group
Group type: EXPERIMENTAL
Intervention: Right temporal, occipital and late central components
Number of subjects: 0
Study 23777757 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall performance on the MATRICS
Number of subjects: 0
Study 20364382 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytoreductive nephrectomy and cytokine therapy
Number of subjects: 0
Study 20364382 — intervention group
Group type: COMPARATOR
Intervention: Cytokine therapy alone
Number of subjects: 0
Study 20364382 — intervention group
Group type: EXPERIMENTAL
Intervention: Nephrectomy and subsequent metastasectomy
Number of subjects: 0
Study 20063527 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherence to the CONSORT statement
Number of subjects: 33
Study 20063527 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequence generation
Number of subjects: 33
Study 20063527 — intervention group
Group type: EXPERIMENTAL
Intervention: Allocation concealment
Number of subjects: 33
Study 20063527 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation
Number of subjects: 33
Study 20063527 — intervention group
Group type: EXPERIMENTAL
Intervention: Blinding
Number of subjects: 33
Study 20063527 — intervention group
Group type: EXPERIMENTAL
Intervention: Sample size
Number of subjects: 33
Study 16847636 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen citrate (TMX) at a 20-mg dosage
Number of subjects: 66
Study 16847636 — intervention group
Group type: COMPARATOR
Intervention: No ovulation-induction drugs (Control)
Number of subjects: 66
Study 12787038 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic corticosteroid therapy with prednisone (50 mg/day) followed by clobetasol ointment plus antimycotics
Number of subjects: 49
Study 12787038 — intervention group
Group type: COMPARATOR
Intervention: Topical treatment with clobetasol plus antimycotics
Number of subjects: 49
Study 11068775 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent ATG (IATG)
Number of subjects: 56
Study 11068775 — intervention group
Group type: COMPARATOR
Intervention: Daily ATG (DATG)
Number of subjects: 56
Study 11068775 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (IATG and DATG)
Number of subjects: 56
Study 8648371 — intervention group
Group type: EXPERIMENTAL
Intervention: Epirubicin (EPI) plus Lonidamine (LND)
Number of subjects: 207
Study 8648371 — intervention group
Group type: COMPARATOR
Intervention: Epirubicin (EPI)
Number of subjects: 207
Study 1482264 — intervention group
Group type: EXPERIMENTAL
Intervention: Labetalol (200 mg twice a day)
Number of subjects: 18
Study 1482264 — intervention group
Group type: COMPARATOR
Intervention: Control group (no labetalol prescribed)
Number of subjects: 18
Study 6094076 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCTZ), 25 mg twice a day (group 1; n = 12)
Number of subjects: 29
Study 6094076 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril, 10 mg twice a day (group 2; n = 12)
Number of subjects: 29
Study 6094076 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril, 10 mg twice a day, with HCTZ, 25 mg twice a day (group 3; n = 5)
Number of subjects: 29
Study 31300571 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial concerns
Number of subjects: 109
Study 31300571 — intervention group
Group type: COMPARATOR
Intervention: Medical priorities
Number of subjects: 109
Study 30010704 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention (aerobic and resistance training program) for 12 weeks
Number of subjects: 77
Study 30010704 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 77
Study 27749542 — intervention group
Group type: EXPERIMENTAL
Intervention: Real acupuncture
Number of subjects: 72
Study 27749542 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 72
Study 24534142 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 9 mg once daily (OD)
Number of subjects: 471
Study 24534142 — intervention group
Group type: COMPARATOR
Intervention: Budesonide 3 mg three times daily (TID)
Number of subjects: 471
Study 24534142 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 9 mg OD
Number of subjects: 471
Study 24534142 — intervention group
Group type: COMPARATOR
Intervention: Budesonide 3 mg TID
Number of subjects: 471
Study 23088451 — intervention group
Group type: EXPERIMENTAL
Intervention: Nominal alignment TKR
Number of subjects: 80
Study 23088451 — intervention group
Group type: COMPARATOR
Intervention: Outlier alignment TKR
Number of subjects: 80
Study 23088451 — intervention group
Group type: COMPARATOR
Intervention: Femoral-tibial rotational mismatch
Number of subjects: 80
Study 19617300 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-based smoking cessation counselling (national model)
Number of subjects: 1518
Study 19617300 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based smoking cessation programme (newly developed)
Number of subjects: 1518
Study 19617300 — intervention group
Group type: COMPARATOR
Intervention: No referral ('do as usual')
Number of subjects: 1518
Study 19617300 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-based smoking cessation counselling
Number of subjects: 1518
Study 19617300 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based smoking cessation programme
Number of subjects: 1518
Study 17387132 — intervention group
Group type: EXPERIMENTAL
Intervention: Tilarginine (1‐mg/kg bolus and 1‐mg/kg per hour 5‐hour infusion)
Number of subjects: 398
Study 16229112 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation of fluoxetine hydrochloride (20 mg dispersible tablet)
Number of subjects: 30
Study 16229112 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation of fluoxetine hydrochloride (20 mg dispersible tablet)
Number of subjects: 30
Study 12394962 — intervention group
Group type: EXPERIMENTAL
Intervention: Afternoon rest (duration, 2:31 ± 1:04 hrs) with opportunity for a nap (duration, 1:07 ± 0:26 hrs, n = 6)
Number of subjects: 11
Study 12394962 — intervention group
Group type: COMPARATOR
Intervention: No afternoon rest
Number of subjects: 11
Study 11603414 — intervention group
Group type: EXPERIMENTAL
Intervention: Human polyvalent immunoglobulin for intravenous administration
Number of subjects: 0
Study 11603414 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of immunoglobulin and plasmapheresis
Number of subjects: 0
Study 11603414 — intervention group
Group type: COMPARATOR
Intervention: Plasmapheresis
Number of subjects: 0
Study 8890204 — intervention group
Group type: EXPERIMENTAL
Intervention: CVD 1203 vaccine (1.5 x 10^8 CFU)
Number of subjects: 32
Study 8890204 — intervention group
Group type: EXPERIMENTAL
Intervention: CVD 1203 vaccine (1.5 x 10^9 CFU)
Number of subjects: 32
Study 8890204 — intervention group
Group type: EXPERIMENTAL
Intervention: CVD 1203 vaccine (1.2 x 10^6 CFU)
Number of subjects: 32
Study 8890204 — intervention group
Group type: EXPERIMENTAL
Intervention: CVD 1203 vaccine
Number of subjects: 32
Study 8890204 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 1537265 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting state (no food intake)
Number of subjects: 10
Study 1537265 — intervention group
Group type: COMPARATOR
Intervention: After eating three main and three in‐between meals
Number of subjects: 10
Study 6321454 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxepin
Number of subjects: 60
Study 6321454 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 30618054 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD4831 135 mg
Number of subjects: 40
Study 30618054 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD4831 405 mg
Number of subjects: 40
Study 30618054 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD4831 (all doses)
Number of subjects: 40
Study 30618054 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 30354631 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrathin bioresorbable polymer sirolimus-eluting stent (BP-SES)
Number of subjects: 677
Study 30354631 — intervention group
Group type: COMPARATOR
Intervention: Thin durable polymer everolimus-eluting stent (DP-EES)
Number of subjects: 677
Study 27782851 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-reflux catheter (ARC)
Number of subjects: 25
Study 27782851 — intervention group
Group type: COMPARATOR
Intervention: Standard microcatheter
Number of subjects: 25
Study 24662234 — intervention group
Group type: COMPARATOR
Intervention: Full range of motion (ROM) squat (F)
Number of subjects: 17
Study 24662234 — intervention group
Group type: EXPERIMENTAL
Intervention: Full ROM with partial ROM squat (FP)
Number of subjects: 17
Study 22497598 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribosomal prophylaxis with Immucytal® (one tablet daily, 8 days a month for 3 months)
Number of subjects: 100
Study 22497598 — intervention group
Group type: COMPARATOR
Intervention: Placebo (same dosage for the same period)
Number of subjects: 100
Study 20530452 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampicin-miconazole-loaded central venous catheter (CVC)
Number of subjects: 223
Study 20530452 — intervention group
Group type: COMPARATOR
Intervention: Standard central venous catheter (CVC)
Number of subjects: 223
Study 18721465 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab treatment
Number of subjects: 130
Study 18721465 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic ileocolic resection
Number of subjects: 130
Study 15796147 — intervention group
Group type: EXPERIMENTAL
Intervention: Icodextrin-based peritoneal dialysis fluid (IPDF)
Number of subjects: 56
Study 15796147 — intervention group
Group type: COMPARATOR
Intervention: Glucose-based peritoneal dialysis fluid (GPDF)
Number of subjects: 56
Study 11921054 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon beta‐1a (30 microg weekly intramuscular injections)
Number of subjects: 383
Study 9926179 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium 1.0 mg/kg
Number of subjects: 349
Study 9926179 — intervention group
Group type: COMPARATOR
Intervention: Succinylcholine 1.0 mg/kg
Number of subjects: 349
Study 8647745 — intervention group
Group type: EXPERIMENTAL
Intervention: Middle latency responses of auditory evoked magnetic fields
Number of subjects: 4
Study 8647745 — intervention group
Group type: EXPERIMENTAL
Intervention: Equivalent current dipole sources
Number of subjects: 4
Study 2186020 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonazepam (0.5-2.0 mg/day)
Number of subjects: 12
Study 2186020 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine (25-50 mg/day)
Number of subjects: 12
Study 2186020 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 12
Study 233174 — intervention group
Group type: EXPERIMENTAL
Intervention: Clostridium welchii type C beta toxoid
Number of subjects: 5030
Study 233174 — intervention group
Group type: COMPARATOR
Intervention: Tetanus toxoid (control)
Number of subjects: 5030
Study 31713469 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 100
Study 31713469 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbapenem long-lasting (4h) infusion
Number of subjects: 100
Study 31713469 — intervention group
Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 100
Study 31185950 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib treatment
Number of subjects: 12
Study 28052588 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirukumab 50 mg by Prefilled Syringe‐UltraSafe Passive® Delivery System (PFS‐U)
Number of subjects: 144
Study 28052588 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirukumab 100 mg by Prefilled Syringe‐UltraSafe Passive® Delivery System (PFS‐U)
Number of subjects: 144
Study 28052588 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirukumab 50 mg by Prefilled Syringe‐SmartJect® Autoinjector (PFS‐AI)
Number of subjects: 144
Study 28052588 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirukumab 100 mg by Prefilled Syringe‐SmartJect® Autoinjector (PFS‐AI)
Number of subjects: 144
Study 28052588 — intervention group
Group type: COMPARATOR
Intervention: Sirukumab 100 mg intravenous (IV) infusion
Number of subjects: 144
Study 28052588 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirukumab 100 mg by PFS‐AI
Number of subjects: 144
Study 28052588 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirukumab (all doses)
Number of subjects: 144
Study 25739844 — intervention group
Group type: EXPERIMENTAL
Intervention: Ankle and midfoot mobilization
Number of subjects: 50
Study 25739844 — intervention group
Group type: COMPARATOR
Intervention: Stretching exercises and ultrasound
Number of subjects: 50
Study 23573882 — intervention group
Group type: EXPERIMENTAL
Intervention: Transperitoneal laparoscopic adrenalectomy (TLA)
Number of subjects: 24
Study 23573882 — intervention group
Group type: COMPARATOR
Intervention: Retroperitoneal laparoscopic adrenalectomy (RLA)
Number of subjects: 24
Study 21991893 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytisine
Number of subjects: 740
Study 19799882 — intervention group
Group type: EXPERIMENTAL
Intervention: Acamprosate (1998 mg/day)
Number of subjects: 56
Study 19799882 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 16963848 — intervention group
Group type: EXPERIMENTAL
Intervention: Twofold illumination PDT scheme (50+50 J/cm)
Number of subjects: 16
Study 16963848 — intervention group
Group type: COMPARATOR
Intervention: Standard PDT regimen (50 J/cm)
Number of subjects: 16
Study 15596567 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabolic syndrome factor score
Number of subjects: 119
Study 15596567 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabolic syndrome
Number of subjects: 119
Study 11713920 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous injection of atropine sulfate
Number of subjects: 4
Study 9209205 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-generated guideline recommendations
Number of subjects: 30
Study 9209205 — intervention group
Group type: COMPARATOR
Intervention: Standard encounter form
Number of subjects: 30
Study 7904003 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine Replacement Therapy (NRT)
Number of subjects: 17703
Study 7904003 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine gum
Number of subjects: 17703
Study 7904003 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal patch
Number of subjects: 17703
Study 7904003 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal spray
Number of subjects: 17703
Study 7904003 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nicotine
Number of subjects: 17703
Study 7904003 — intervention group
Group type: COMPARATOR
Intervention: Control interventions
Number of subjects: 17703
Study 2923763 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride 10 mg i.v. in 5% dextrose 20 ml
Number of subjects: 20
Study 2923763 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 786352 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (40 mg)
Number of subjects: 21
Study 786352 — intervention group
Group type: EXPERIMENTAL
Intervention: Practolol (120 mg)
Number of subjects: 21
Study 786352 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 30789006 — intervention group
Group type: EXPERIMENTAL
Intervention: Eye-hand-decoupled task
Number of subjects: 62
Study 30789006 — intervention group
Group type: COMPARATOR
Intervention: Direct interaction task
Number of subjects: 62
Study 28551445 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal pain regimen
Number of subjects: 138
Study 28551445 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 138
Study 25937373 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic robot‐assisted radical prostatectomy (LRARP)
Number of subjects: 304
Study 25937373 — intervention group
Group type: COMPARATOR
Intervention: Open retropubic radical prostatectomy (ORP)
Number of subjects: 304
Study 25937373 — intervention group
Group type: EXPERIMENTAL
Intervention: Both ORP and LRARP
Number of subjects: 304
Study 23320650 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous magnesium sulphate (4930 mg = 20 mmol magnesium) administered 60 min before and 6 hours after ERCP
Number of subjects: 502
Study 23320650 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered 60 min before and 6 hours after ERCP
Number of subjects: 502
Study 21414125 — intervention group
Group type: EXPERIMENTAL
Intervention: HAL TURB (fluorescence-guided transurethral resection using hexaminolaevulinate)
Number of subjects: 233
Study 21414125 — intervention group
Group type: COMPARATOR
Intervention: WL TURB (conventional transurethral resection in white light)
Number of subjects: 233
Study 21414125 — intervention group
Group type: EXPERIMENTAL
Intervention: HAL TURB
Number of subjects: 233
Study 21414125 — intervention group
Group type: COMPARATOR
Intervention: WL TURB
Number of subjects: 233
Study 19326367 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term response information used for adaptive randomization in survival trials
Number of subjects: 0
Study 19326367 — intervention group
Group type: EXPERIMENTAL
Intervention: Bayesian model using prior clinical information and dynamic updates
Number of subjects: 0
Study 19326367 — intervention group
Group type: EXPERIMENTAL
Intervention: Interim monitoring and final decision making based on survival outcomes
Number of subjects: 0
Study 17890730 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose INR self-management
Number of subjects: 2673
Study 17890730 — intervention group
Group type: COMPARATOR
Intervention: Conventional INR control
Number of subjects: 2673
Study 15481562 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity home-based physical therapy (once a week for 10 weeks)
Number of subjects: 20
Study 15481562 — intervention group
Group type: COMPARATOR
Intervention: Control group (delayed intervention after 10 weeks)
Number of subjects: 20
Study 11853284 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid (Hyalgan 2 ml/wk for 4 doses)
Number of subjects: 0
Study 11853284 — intervention group
Group type: COMPARATOR
Intervention: Placebo (2 ml of normal saline)
Number of subjects: 0
Study 9763324 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual toothbrush (Butler 411)
Number of subjects: 97
Study 9763324 — intervention group
Group type: COMPARATOR
Intervention: Electric toothbrush (Braun/Oral-B Ultra Plaque Remover-D9)
Number of subjects: 97
Study 9763324 — intervention group
Group type: EXPERIMENTAL
Intervention: Electric toothbrush (Braun/Oral-B Plaque Remover-D7)
Number of subjects: 97
Study 9763324 — intervention group
Group type: EXPERIMENTAL
Intervention: Electric toothbrush (Braun/Oral-B Ultra Plaque Remover-D9) with different types of endrounding
Number of subjects: 97
Study 9763324 — intervention group
Group type: EXPERIMENTAL
Intervention: Electric toothbrush (Braun/Oral-B D7 at 2800 rot/min) and D9 at 3600 rot/min
Number of subjects: 97
Study 7825006 — intervention group
Group type: EXPERIMENTAL
Intervention: Dioctahedral smectite (DS) with rehydration
Number of subjects: 66
Study 7825006 — intervention group
Group type: COMPARATOR
Intervention: Oral or intravenous rehydration (Control)
Number of subjects: 66
Study 3254767 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral high-frequency oscillation (OHFO) at 8 Hz
Number of subjects: 12
Study 3254767 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral high-frequency oscillation (OHFO) at 16 Hz
Number of subjects: 12
Study 3254767 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral high-frequency oscillation (OHFO) at 8 Hz, 12 Hz, and 16 Hz
Number of subjects: 12
Study 3254767 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral high-frequency oscillation (OHFO)
Number of subjects: 12
Study 31462117 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Tramadol 50 mg, 1 hour prior to the procedure
Number of subjects: 100
Study 31462117 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 30088558 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran
Number of subjects: 37
Study 30088558 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 37
Study 26881073 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-PSG alveolar NO concentration (CANO) in OSA patients
Number of subjects: 82
Study 26881073 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-PSG alveolar NO concentration (CANO) in OSA patients
Number of subjects: 82